Cytokinetics
CYTK
61.12
-0.23
-0.37%
Cytokinetics
US · CYTK
#1564 by market cap
Listed 1970
61.12
-0.23
-0.37%
Live - 5344 symbols - heartbeat 297s ago
· 2026-10-08 07:00
Pre-market
62.49
+2.24%
After-hours
61.12
0.00%
- Market cap
- 8.50B
- P/E (TTM)i
- -8.47
- P/Bi
- -48.97
- EPSi
- -6.54
- Div yieldi
- 0.00%
- 52W posi
- 20%
Reader sentiment
Are you bullish or bearish on CYTK?
Anonymous reader poll. Unscientific, not investment advice.
Recent news
-
Rating change
Needham Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $102Market Newswire · 2026/7/31
-
Rating change
Truist Financial Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $112Market Newswire · 2026/9/2
-
Wells Fargo Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $105Market Newswire · 2026/10/4
-
Rating change
B. Riley Securities Sticks to Their Buy Rating for Cytokinetics (CYTK)TipRanks · 2026/7/31
-
Cytokinetics(CYTK.US) Officer Sells US$7.34 Million in Common StockMarket Newswire · 2026/9/16
-
Rating change
Truist Financial Maintains Cytokinetics(CYTK.US) With Buy Rating, Announces Target Price $112Market Newswire · 2026/8/13
-
Rating change
Barclays Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $110Market Newswire · 2026/8/27
-
Rating change
Analysts' Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN), Cytokinetics (CYTK) and Biohaven Ltd. (BHVN)TipRanks · 2026/9/10
-
Rating change
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $85 to $140Market Newswire · 2026/9/1
-
Rating change
RBC Capital Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $112Market Newswire · 2026/9/10
-
Rating change
J.P. Morgan Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $103Market Newswire · 2026/8/13
-
Rating change
BofA Securities Maintains Cytokinetics(CYTK.US) With Hold Rating, Maintains Target Price $85Market Newswire · 2026/8/31
-
Form 144 | Cytokinetics(CYTK.US) Insider Proposes to Sell 7.09 Million in Common StocksMarket Newswire · 2026/9/16
-
Rating change
B. Riley Securities Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $146Market Newswire · 2026/7/31
-
H.C. Wainwright Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $140Market Newswire · 2026/10/5
-
Rating change
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $100 to $140Market Newswire · 2026/8/8
-
Needham Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $112Market Newswire · 2026/10/5
-
Rating change
J.P. Morgan Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $103Market Newswire · 2026/8/13
-
Rating change
J.P. Morgan Maintains Cytokinetics(CYTK.US) With Buy RatingMarket Newswire · 2026/8/20
-
Rating change
Barclays Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $110Market Newswire · 2026/8/14
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-10-08 07:00:10 · For reference only, not investment advice and not tailored to your situation.